All of Us Research Program
Do you want to change the future of health? The Froedtert & MCW health network is part of the National Institutes of Health All of Us Research Program. It has a simple mission — speed up health research breakthroughs. To do this, All of Us is asking one million people to share their health information. Learn how you can help make a difference by joining the All of Us Research Program.
65 results for "Cancer" and "Endocrine Cancers"
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417 in Combination With Dexamethasone and Carfilzomib/Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to
Determine the Safety and Efficacy of BGB-11417 in Combination With Dexamethasone andCarfilzomib/Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14)
Determine the Safety and Efficacy of BGB-11417 in Combination With Dexamethasone andCarfilzomib/Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14)
Protocol No
BEIGENE-BGB-11417-105
A Randomized Phase III Trial of Olanzapine Versus Megestrol Acetate for Cancer-Associated Anorexia
Olanzapine vs Megestrol Acetate for the Treatment of Loss of Appetite Among Advanced Cancer Patients
Protocol No
ALLIANCE-A222004-ANOREXIA
Phase 2, Prospective, Single Arm Medical Food Study to Evaluate a Standardized Nonessential Amino Acid Restriction (NEAAR) Medical Food for the Dietary Management of Metastatic Pancreatic Cancer
Medical Food for the Dietary Management of Metastatic Pancreatic Cancer
Protocol No
FAETH-THERAPEUTICS-NEAAR-001
Sub Category
A Phase 1b/2 Study Of AVB-S6-500 In Combination with Cabozantinib, AVB-S6-500 In Combination with Cabozantinib and Nivolumab, and AVB-S6-500 Monotherapy in Patients with Advanced or Metastatic Clear Cell Renal Cell Carcinoma
Safety and Efficacy Study of AVB-S6-500 in Patients With Advanced Clear Cell Renal Cell Carcinoma
Protocol No
ARAVIVE-AVB500-RCC-003
Sub Category
A Randomized Phase 2 Study Of Erdafitinib Versus Investigator Choice Of Intravesical Chemotherapy In Subjects Who Received Bacillus Calmette-Guérin (BCG) And Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) And FGFR Mutations Or Fusions
Erdafitinib vs Investigator Choice of Intravesical Chemo for NMIBC Pts Who Recurred After BCG
Protocol No
JANSSEN-42756493BLC2003-THOR-2
Sub Category
High Dose Re-Irradiation Utilizing Advanced Defromable Image Registration (DIR) and Individualized Organ At Risk (OAR) Dose Calculations with Organ Specific Toxicity Analysis (Re-DIRICT)
A Phase II study of Re-Irradiation Utilizing DIR and OAR Dose Calculations with Organ Specific Toxicity Analysis
Protocol No
IIT-GORE-REDIRICT
Phase 2 Trial Of 5-Fluorouracil, Oxaliplatin And Liposomal Irinotecan (Plus Trastuzumab For HER2-Positive Disease) During 1st Line Treatment Of Advanced Esophageal And Gastric Adenocarcinoma
P2 5-FU, Oxaliplatin & Liposomal Irinotecan (Nal-IRI) in 1st Line Advanced Esophageal & Gastric Cancers
Protocol No
WON-UW19029
Sub Category
A Phase 3, Open-Label, Randomized Study of Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients with Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements FOENIX-CCA3
Futibatinib Vs Gemcitabine-Cisplatin Chemotherapy as 1st-Line Treatment of Patients With Advanced Cholangiocarcinoma
Protocol No
TAIHO-TAS-120-301-FOENIX-CCA3
Sub Category
Phase III Trial of Immunotherapy-Based Combination Therapy with or Without Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma (Probe Trial)
Immunotherapy-Based Drug Combo w wo Surgery to Remove Kidney in Mets Kidney Cancer
Protocol No
SWOG-S1931-PROBE-TRIAL
Sub Category
A Phase 1, Open-Label, Dose-Escalation, and Dose-Expansion Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SRK-181 Administered Alone or in Combination with a Checkpoint Inhibitor in Patients with Locally Advanced or Metastatic Solid Tumors (Dragon)
Evaluate the safety and tolerability of single-agent SRK-181 and determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and evaluate dose-limiting toxicities (DLTs) of single-agent SRK-181.
Protocol No
SCHOLARROCK-SRK-181-001
STEEL: A Randomized Phase II Trial of Salvage Radiotherapy with Standard vs Enhanced Androgen Deprivation Therapy (with Enzalutamide) in Patients with Post-Prostatectomy PSA Recurrences with Aggressive Disease Features
Salvage Radiotherapy w or w/o Enzalutamide in Recurrent Prostate Cancer Following Surgery
Protocol No
RTOG-FND-3506-STEEL
Sub Category
MRI-ENHANCE MRI-Guided Adaptive Radiation Therapy for Organ Preservation in Rectal Cancer
This project is being done to to test an experimental treatment for your rectal adenocarcinoma called Magnetic Resonanceguided Adaptive Radiation Therapy in addition to the standard radiation therapy for your type of cancer.
Protocol No
IIT-HALL-MRI-ENHANCE
Sub Category
A Phase II Study of Cabozantinib and Temozolomide in Patients with Unresectable or Metastatic Leiomyosarcoma and Other Soft Tissue Sarcomas
Cabozantinib and Temozolomide for the Treatment of Unresectable or Metastatic Leiomyosarcoma or Other Soft Tissue Sarcoma
Protocol No
NU-19S01
Sub Category
A Phase 1, Multi-Center, Open-Label, Dose Finding Study Of CC-92328 In Subjects With Relapsed and/or Refractory Multiple Myeloma
To determine the safety and tolerability of CC-92328 in subjects with R/R MM. To define the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of CC-92328 in subjects with R/R MM.
Protocol No
CELGENE-CC-92328-MM-001
Phase 1/2 Study Of REGN4336 (A PSMAXCD3 Bispecific Antibody) Administered Alone Or In Combination With Cemiplimab In Patients With Metastatic Castration-Resistant Prostate Cancer
To assess the safety, tolerability, and PK and to determine RP2DR of REGN4336
separately as monotherapy or in combination with cemiplimab.
separately as monotherapy or in combination with cemiplimab.
Protocol No
REGENERON-R4336-ONC-20104
A Phase 1, Open-Label, Multicenter Study of HMPL-306 in Advanced Hematological Malignancies with Isocitrate Dehydrogenase (IDH) Mutations
To evaluate the safety and tolerability of HMPL-306 in patients with advanced hematological malignancies that harbor IDH mutations and characterize safety and tolerability to determine RP2D of HMPL-306 in patients with advanced hematological malignancies that harbor IDH mutations.
Protocol No
HMP-2020-306-GLOB1
A Phase Ib/II, Open-label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-based Treatment Combinations in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)
Protocol No
HOFFMANN-WO39608-MORPHEUS
A Phase 1/2, First-In-Human, Multi-Part, Open-Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of DF6002 as a Monotherapy and in Combination with Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors, and Expansion in Selected Indications
The purpose of this study is to test the levels of the investigational medicine (not approved by the FDA), named DF6002, in your blood, the safety of DF6002, and how people with some types of solid tumor cancers respond to the investigational medicine.
Protocol No
DRAGONFLY-DF6002-001
A Phase 1/2, Dose Escalation Safety and Tolerability Study of AO-176 as Monotherapy and in Combination with Bortezomib and Dexamethasone in Adults with Relapsed or Refractory Multiple Myeloma
In this study the focus of Phase 1 is safety, answering the question of which dose is tolerable. In Phase 2 the focus is on safety and whether the study drug, in combination with other drugs, help your cancer not continue or progress, answering the question of whether the study drug is effective.
Protocol No
ARCH-AO-176-102
A Phase I, First-in-human, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-1287 Administered Twice Daily for 14 Days to Patients with Advanced Solid Tumors
Phase I, First-in-human Study of Oral TP-1287 in Patients With Advanced Solid Tumors
Protocol No
TOLERO-TP-1287-101
A Phase I Study of Lintuzumab-Ac225 in Combination with CLAG-M Chemotherapy in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)
Lintuzumab-Ac225 in Combination With CLAG-M Chemotherapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Protocol No
IIT-ABEDIN-LINTUZUMAB-AML